VAISHALI CHAWLA
Independent Consultant · Delhi, India · Working with US and global deal teams
Financial modelling and transaction analysis for investors, SPAC sponsors and finance teams.
I work as an embedded analyst alongside PE, VC and SPAC Sponsors and corporate finance teams: building models, stress-testing projections, analysing PIPE financing and dilution, and assessing listing feasibility, so principals can act on numbers they can defend.
SERVICES
INDEPENDENT ANALYSIS THAT TESTS THE NUMBERS BEHIND INVESTMENT DECISIONS
SPAC Target Evaluation & Transaction Support
Target research and valuation, Nasdaq listing eligibility, and PIPE and bridge financing models built directly from term sheets, covering conversion mechanics, investor returns, pro forma ownership and dilution. I also review existing transaction models.
Financial Modelling, FP&A & Forecasting
Driver-based models built on how the business actually grows (patients, customers, agents, take rates), plus integrated operating models, budgeting, rolling forecasts and budget-versus-actual analysis for investors and finance teams.
Valuation & Investment Analysis
DCF, comparable-company and precedent-transaction valuation, including risk-adjusted valuation of drug pipelines. Every key assumption is sourced and tested against management’s projections.
Investment Research & Commercial Due Diligence
Bottom-up market sizing from epidemiology and demographics, competitive benchmarking, and research-style investment theses, with particular depth in healthcare, biopharma and medical devices.
Process Design & AI Workflow Enablement
Clear standards and SOPs for analytical work, increasingly built as AI-ready workflows, so models, research and deal analysis stay consistent whoever does the work.
SECTOR DEPTH
Healthcare & Biopharma · Medical Devices & Diagnostics · Digital Health · Semiconductors & Edge AI · Consumer · Marketplaces · Travel & Hospitality Tech
ABOUT ME
I’m an independent financial analyst working directly with SPAC sponsors, private equity and venture capital investors on the analysis behind transaction decisions.
Since 2023, I’ve served as an embedded analytical resource for SPAC sponsor teams evaluating acquisition targets across healthcare, medical devices, digital health and consumer sectors. That work spans target financial models and bottom-up revenue forecasts, comparable-company benchmarking, market sizing, Nasdaq listing eligibility, and pro forma capitalization, dilution and PIPE financing analysis.
Beyond SPACs, I build operating models, DCF and comparable-company valuations, and commercial due diligence for companies with enterprise values of roughly $500M to $2B+.
The common thread is work where data is incomplete and assumptions have to be researched and defended, not lifted from a management deck. I work directly with principals, under NDA, and scope each engagement around the decision it needs to support.
FRM Charterholder · CFA Level I · CA Final (Group 2 passed)
Have a research or modelling problem?
If you’re evaluating an investment, building a model, analysing a transaction, or facing a problem where the data is incomplete and the assumptions need defending, let’s discuss it.
I reply within one business day, wherever you’re based.
Happy to sign an NDA before our first call. I work with teams across the US, UK, Middle East and Asia-Pacific, and align my hours to your time zone for calls, reviews and deal deadlines.